DK1025124T3 - Human interferon-alfa-analoge med lav toksicitet - Google Patents

Human interferon-alfa-analoge med lav toksicitet

Info

Publication number
DK1025124T3
DK1025124T3 DK98952350T DK98952350T DK1025124T3 DK 1025124 T3 DK1025124 T3 DK 1025124T3 DK 98952350 T DK98952350 T DK 98952350T DK 98952350 T DK98952350 T DK 98952350T DK 1025124 T3 DK1025124 T3 DK 1025124T3
Authority
DK
Denmark
Prior art keywords
alpha
low toxicity
human interferon
analogs
interferon
Prior art date
Application number
DK98952350T
Other languages
Danish (da)
English (en)
Inventor
Howard M Johnson
Carol H Pontzer
Lorelie H Villarete
Jackeline Campos
Original Assignee
Pepgen Corp
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepgen Corp, Univ Florida filed Critical Pepgen Corp
Application granted granted Critical
Publication of DK1025124T3 publication Critical patent/DK1025124T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK98952350T 1997-10-20 1998-10-20 Human interferon-alfa-analoge med lav toksicitet DK1025124T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,395 US6204022B1 (en) 1996-04-12 1997-10-20 Low-toxicity human interferon-alpha analogs
PCT/US1998/021936 WO1999020653A1 (en) 1997-10-20 1998-10-20 Low-toxicity human interferon-alpha analog

Publications (1)

Publication Number Publication Date
DK1025124T3 true DK1025124T3 (da) 2008-10-06

Family

ID=25495373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98952350T DK1025124T3 (da) 1997-10-20 1998-10-20 Human interferon-alfa-analoge med lav toksicitet

Country Status (13)

Country Link
US (1) US6204022B1 (de)
EP (1) EP1025124B1 (de)
JP (2) JP2001520238A (de)
KR (2) KR100861007B1 (de)
CN (1) CN1240717C (de)
AT (1) ATE402957T1 (de)
AU (1) AU744774B2 (de)
CA (1) CA2308116C (de)
DE (1) DE69839812D1 (de)
DK (1) DK1025124T3 (de)
ES (1) ES2310931T3 (de)
TW (1) TW593336B (de)
WO (1) WO1999020653A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
EP1212364A1 (de) * 1999-08-27 2002-06-12 University Of Florida STOFFE UND VERFAHREN ZUR HEMMUNG DER IgE PRODUKTION
AU2001266557A1 (en) * 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
BR0115392A (pt) * 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
KR20040022244A (ko) * 2001-08-12 2004-03-11 펩젠 코포레이션 하이브리드 인터페론/인터페론 타우 단백질, 조성물 및사용방법
CN100438870C (zh) * 2001-11-09 2008-12-03 精达制药公司 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2004218407A1 (en) * 2003-03-03 2004-09-16 Board Of Regents, The University Of Texas System Methods and compositions involving MDA-7
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
CA2548220A1 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101166539B (zh) * 2005-02-08 2012-01-04 得克萨斯大学体系董事会 用于治疗癌症的涉及mda-7的组合物和方法
KR20080037656A (ko) * 2005-06-20 2008-04-30 펩젠 코포레이션 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
WO2007098106A2 (en) * 2006-02-17 2007-08-30 Pepgen Coporation Respiratory tract delivery of interferon-tau
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US7655216B2 (en) * 2007-02-26 2010-02-02 University of Pittsburgh - of the Commonwealth of Higher Education Vaccine for activating helper function of CD8+ Tcells
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
BRPI1012951A2 (pt) 2009-06-09 2016-07-26 Defyrus Inc "administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0146903A3 (de) 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
EP0240224A3 (de) 1986-03-31 1989-02-01 Interferon Sciences, Inc. Alpha-Interferon-Analogon
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW391983B (en) 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them

Also Published As

Publication number Publication date
KR20010031206A (ko) 2001-04-16
KR100861007B1 (ko) 2008-09-30
US6204022B1 (en) 2001-03-20
KR100586625B1 (ko) 2006-06-07
CA2308116C (en) 2010-12-14
ES2310931T3 (es) 2009-01-16
JP2001520238A (ja) 2001-10-30
EP1025124B1 (de) 2008-07-30
EP1025124A1 (de) 2000-08-09
TW593336B (en) 2004-06-21
DE69839812D1 (de) 2008-09-11
AU9807298A (en) 1999-05-10
AU744774B2 (en) 2002-03-07
ATE402957T1 (de) 2008-08-15
KR20060015701A (ko) 2006-02-17
CN1240717C (zh) 2006-02-08
CN1276797A (zh) 2000-12-13
JP2008247926A (ja) 2008-10-16
WO1999020653A1 (en) 1999-04-29
CA2308116A1 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DK0946191T3 (da) Anvendelse af GLP-1-analoge og -derivater indgivet perifert til regulering af fedme
PL347932A1 (en) Interferon-beta fusion proteins and uses
ES2130574T3 (es) Agentes de restriccion de las citoquinas.
NO20100324L (no) Fremgangsmate for trinnvis festing av polyetylenglykol (PEG) andeler i serie til et polypeptid
ATE284413T1 (de) Therapeutische peptid derivate
GB9806632D0 (en) Peptide factor
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
NO20050066L (no) Pegylert T20 polypeptid
BG104266A (en) Aminoterminally incised mcp-2 as haemokin antagonists
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
ATE110742T1 (de) Peptid-verbindungen.
DE3886517T2 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DK1150703T3 (da) Behandling af multipel sclerose med chaperonin 10 og beta-interferon
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
ATE105841T1 (de) 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen.
EE200000694A (et) Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon
DE69529235T2 (de) Menschliche dnase i varianten
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
AU2003274173A1 (en) Peptides and recombinant proteins mimicking interferons
ATE207496T1 (de) Neue peptide und nootroper wirkstoff